A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC — Stella

Recruiting

Back to Castration-resistant Prostate Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Australia

Wollongong Hospital, Wollongong, New South Wales

Icon Cancer Centre Hollywood, Nedlands, Western Australia

Key details

Phase

Early testing / Safety & dosing

Sponsor

Radiopharm Theranostics, Ltd

Enrollment target

~73 participants

Started

March 2026

Primary completion

November 2028

Age range

18 Years and older

Sex

Male only

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov